Literature DB >> 32419527

Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma.

Caterina Lanna1, Claudia Galluzzi2, Arianna Zangrilli1, Mauro Bavetta1, Luca Bianchi1, Elena Campione1.   

Abstract

BACKGROUND: When psoriasis affects scalp, nails, palms and soles, it is considered difficult to treat and causes severe impairment of life quality.
OBJECTIVE: We evaluated which difficult site most impacts on the patient's quality of life and how quality of life changes during treatment.
METHODS: We conducted a prospective observational study in patients receiving adalimumab over a 24 weeks period, through assessment at weeks 0, 4 and 24 using PASI, PAIN VAS, ITCH VAS, DLQI, NAPSI, PSSI. Pearson correlation was used to evaluate the relationship between the various measurements on the basis of three different deltas (between T0 and T24, between T0 and T4, between T0 and average between T4 and T24).
RESULTS: The correlation matrix between T0 and T24 shows a significant correlation between delta PASI and delta ITCH and delta ITCH and delta DLQI and a significant correlation between ITCH delta and DLQI delta and a correlation close to significance between DLQI and NAPSI.
CONCLUSION: We identified itching as a mediator between the cutaneous extension of psoriasis and the impact on quality of life. We also documented the predominant role of nail psoriasis in defining the impact on the quality of life of the psoriatic patient.

Entities:  

Keywords:  Psoriasis; adalimumab; itching; quality of life

Mesh:

Substances:

Year:  2020        PMID: 32419527     DOI: 10.1080/09546634.2020.1770175

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  3 in total

1.  Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.

Authors:  Marco Galluzzo; Marina Talamonti; Arnaldo Cioni; Virginia Maffei; Ruslana Gaeta Shumak; Lorenzo Tofani; Luca Bianchi; Elena Campione
Journal:  J Clin Med       Date:  2022-05-07       Impact factor: 4.964

Review 2.  Stigmatization in Patients With Psoriasis: A Mini Review.

Authors:  Hanlin Zhang; Zihan Yang; Keyun Tang; Qiuning Sun; Hongzhong Jin
Journal:  Front Immunol       Date:  2021-11-15       Impact factor: 7.561

3.  Adalimumab biosimilar in a pediatric patient: Clinical and in vivo reflectance confocal microscopy evaluation.

Authors:  Matteo Megna; Alessia Villani; Luca Potestio; Elisa Camela; Gabriella Fabbrocini; Sonia Sofia Ocampo-Garza
Journal:  Dermatol Ther       Date:  2022-07-09       Impact factor: 3.858

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.